Weill Cornell Physicians at Brooklyn Heights — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$71	1
2024	Research	$223	2
2022	Research	$355	2
2021	Research	$44,745	2
2020	Research	$90	1
2019	Research	$21,084	1

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $45,129 6 payments
Amgen Inc. $21,084 1 payment
Ucb SA $355 2 payments

Studies the money was for Research payments · program years 2019–2025

A Two-Year, Phase III Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 MG S.C. Secukinumab Versus Placebo, in Combination With Soc Therapy, in Patients With Active Lupus Nephritis $44,697 3 payments
Enbrel RA Remission Study $21,084 1 payment
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (Gca) $361 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $210 1 payment
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $146 1 payment
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien $71 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.